Abstract
Despite the recent advances in medical therapy and coronary revascularization procedures, coronary artery disease (CAD) remains the major cause of morbidity and mortality in the developing countries. In patients with severe CAD, persistent myocardial ischemia in hibernated myocardium resulted in progressive loss of cardiomyocytes with development of heart failure. As a result, therapeutic approaches to enhance neovascularization are being underwent intensive investigation. Recent experimental studies have demonstrated adult bone marrow (BM) can induce neovascularization in ischemic myocardium can improve heart function. These findings have prompted the development of different cellular transplantation approaches for heart diseases refractory to conventional therapy after myocardial infarction. Although the initial pilot clinical trials have shown potential clinical benefit of BM therapy for therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy remains unclear. Furthermore, in order to acquire more optimized quality and quantity of BM derived stem cell for myocardial regeneration, several issues remain to be addressed, such as the development of a more efficient method of stem cells identification, purification and expansion. Emerging, rationally designed, randomized clinical trials are required to assess the clinical implication of BM derived stem cells therapy in treatment of CAD.
Keywords: Coronary artery disease (CAD), hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), Chronic Myocardial Ischemia, granulocyte macrophage colony-stimulating factor (GM-CSF)
Current Vascular Pharmacology
Title: Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Volume: 5 Issue: 2
Author(s): Hung-Fat Tse, Kai-Hang Yiu and Chu-Pak Lau
Affiliation:
Keywords: Coronary artery disease (CAD), hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), Chronic Myocardial Ischemia, granulocyte macrophage colony-stimulating factor (GM-CSF)
Abstract: Despite the recent advances in medical therapy and coronary revascularization procedures, coronary artery disease (CAD) remains the major cause of morbidity and mortality in the developing countries. In patients with severe CAD, persistent myocardial ischemia in hibernated myocardium resulted in progressive loss of cardiomyocytes with development of heart failure. As a result, therapeutic approaches to enhance neovascularization are being underwent intensive investigation. Recent experimental studies have demonstrated adult bone marrow (BM) can induce neovascularization in ischemic myocardium can improve heart function. These findings have prompted the development of different cellular transplantation approaches for heart diseases refractory to conventional therapy after myocardial infarction. Although the initial pilot clinical trials have shown potential clinical benefit of BM therapy for therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy remains unclear. Furthermore, in order to acquire more optimized quality and quantity of BM derived stem cell for myocardial regeneration, several issues remain to be addressed, such as the development of a more efficient method of stem cells identification, purification and expansion. Emerging, rationally designed, randomized clinical trials are required to assess the clinical implication of BM derived stem cells therapy in treatment of CAD.
Export Options
About this article
Cite this article as:
Tse Hung-Fat, Yiu Kai-Hang and Lau Chu-Pak, Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis, Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368299
DOI https://dx.doi.org/10.2174/157016107780368299 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Surgical Management of Heart Failure
Current Cardiology Reviews Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function
Current HIV Research Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Collagen Receptor Integrins: Rising to the Challenge
Current Drug Targets Unravelling the Genetic Susceptibility to Develop Ligament and Tendon Injuries
Current Stem Cell Research & Therapy Inflammation, Atrial Fibrillation and Cardiac Surgery: Current Medical and Invasive Approaches for the Treatment of Atrial Fibrillation
Current Pharmaceutical Design Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Current Radiopharmaceuticals Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Effects of Pulmonary Blood Flow on Respiratory Mechanics: Measurements by the End-Inflation Occlusion Method in Healthy Rats After Acute Blood Volume Expansion
Current Respiratory Medicine Reviews Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety